Tanshinone IIA Reduces the Risk of Alzheimer’s Disease by Inhibiting Inos, MMP-2 and NF-κBp65 Transcription and Translation in the Temporal Lobes of Rat Models of Alzheimer’s Disease

Ping Jiang,Chunbo Li,Zhenghua Xiang,Binghua Jiao

DOI: https://doi.org/10.3892/mmr.2014.2254

IF: 3.423

2014-01-01

Molecular Medicine Reports

Abstract:Tanshinone IIA (Tan IIA), one of the major active constituents of the medicinal herb Salvia miltiorrhiza, has been reported to possess neuroprotective effects against the pathological features of Alzheimer's disease (AD), but the molecular mechanism underlying this effect remains unclear. To examine the effect of Tan IIA on AD, as well as the underlying molecular mechanisms, in vivo animal experiments and in vitro molecular biology investigations were employed in the present study. Firstly, a rat model of AD was successfully established by direct injection of the amyloid beta protein (A beta) and then these rats were administered an interventional treatment of Tan IIA. The learning and memory ability of rats was evaluated in four groups (Control, Sham, AD and Tan IIA) utilizing a Morris water maze test. Quantitative (q)PCR was employed to detect the mRNA expression of inducible nitric oxide synthase (iNOS), matrix metalloproteinase-2 (MMP-2) and nuclear transcription factor kappa (NF-kappa Bp65) in temporal lobe tissues and protein expression was determined with western blot analysis. In addition, association analyses between iNOS, MMP-2 and NF-kappa Bp65 at a transcriptional and translational level were performed utilizing Spearman's correlation analysis. In the present study, the results revealed that rats in the AD group demonstrated significant disruptions in learning and memory ability, and the symptoms were evidently reduced by Tan IIA. Furthermore, the upregulation of iNOS, MMP-2 and NF-kappa Bp65 at a transcriptional and translational level in AD rats was distinctly inhibited by Tan IIA. Therefore, it was concluded that iNOS, MMP-2 and NF-kappa Bp65 are involved in AD development, and Tan IIA may reduce AD risk by inhibiting transcription and translation of these genes. Furthermore, the positive correlation of iNOS and MMP-2 with NF-kappa Bp65, respectively, provides evidence supporting the hypothesis that Tan IIA reduces AD risk by inhibiting iNOS and MMP-2 at a transcriptional and translational level through the NF-kappa B pathway. In summary, Tan HA is an effective neuroprotective agent for AD therapy, and iNOS, MMP-2 and NF-kappa Bp65 may be the potential molecular targets for manipulating this effect therapeutically.